Piperlongumine: A Novel Inhibitor of Androgen Receptor Signaling
Piperlongumine: A Novel Inhibitor of Androgen Receptor Signaling
批准号:
8302819
负责人:
VLADIMIR M KOLENKO
金额:
$8.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-09 至 2013-06-30
关键词:
AblationAccountingAffectAndrogen AntagonistsAndrogen ReceptorAndrogensBlack PepperCell ProliferationCessation of lifeClinical ResearchDiagnosisDiseaseDisease ProgressionExhibitsFailureGrowthHeat-Shock Proteins 90HormonalHormonesHumanIndolentLNCaPMalignant neoplasm of prostateMediatingMolecularMolecular ChaperonesPTEN genePathway interactionsPatientsPhenotypePlayProstateProstatic TissueReceptor ActivationReceptor SignalingRegimenRoleStagingSystemic TherapyTestingTherapeuticTimeTransgenic MiceVariantWorkXenograft Modelabirateroneadvanced diseasecancer cellcancer initiationcancer riskdeprivationhormone therapyin vivoin vivo Modelinhibitor/antagonistmouse modelmulticatalytic endopeptidase complexnoveloverexpressionprostate cancer preventionprostate carcinogenesisprotein protein interactionreceptorreceptor expressionresearch studytumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The burden of prostate cancer (PC) is tremendous, accounting for approximately 220,000 new cases and 32,050 deaths in the US in 2010 alone. In many patients, PC exhibits an indolent biologic phenotype with a prolonged course-in some cases, extending over 15 years following the initial diagnosis. Thus, the opportunity to intervene early and alter the course and progression of this disease is readily available. Androgen receptor (AR) signaling plays a crucial role in the normal growth of the prostate as well as in PC initiation and progression. Thus, modulation of AR activation and expression represents a logical target for PC prevention and treatment. Recent clinical studies demonstrate that pharmacological inhibition of AR signaling reduces PC risk. However, AR- mediated functions are not completely abrogated by existing hormone therapies. Therapeutic failure is often accompanied by molecular alterations of the AR, including AR overexpression as well as expression of constitutively active AR variants. Our experiments demonstrate for the first time that piperlongumine (PL), a naturally occurring derivative of black pepper, induces rapid AR degradation through a proteasome-mediated pathway which coincides with inhibition of AR transcriptional activity and reduced proliferation of hormone- dependent LNCaP PC cells. We hypothesize that PL can inhibit prostate carcinogenesis at both initiation and advanced disease stages via depletion of the AR either alone or in combination with current androgen deprivation therapeutic regimens. Indeed, hormone ablation and depletion of AR may have a complementary effect on the inhibition of prostate carcinogenesis. The overall objective of this application is to explore the mechanisms of PL- mediated AR depletion and to test PL efficacy for the primary and secondary PC prevention. To test our hypothesis and to evaluate the therapeutic potential of PL for prostate cancer prevention, we propose the following Specific Aims: Aim 1: To investigate the mechanism of PL-mediated AR depletion in prostate cancer cells. Specific Aim 2: To investigate the effect of PL on primary and secondary PC prevention using in vivo models.
PUBLIC HEALTH RELEVANCE: Androgen receptor signaling plays a crucial role in the normal growth of prostatic tissue as well as in prostate cancer initiation and progression. Our work demonstrates for the first time that piperlongumine, a naturally occurring derivative of black pepper, induces rapid androgen receptor degradation in prostate cancer cells through a proteasome-mediated pathway which coincides with reduced functional activity of androgen receptor signaling and decreased cell proliferation. The overall objective of this application is t explore the mechanisms of piperlongumine-mediated androgen receptor depletion and to test piperlongumine efficacy for the primary and secondary prostate cancer prevention.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of cholesterol homeostasis in enzalutamide resistance
-
批准号:10065498
-
项目类别:
-
资助金额:$9.35万
-
财政年份:2019
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Piperlongumine: A Novel Inhibitor of Androgen Receptor Signaling
-
批准号:8507654
-
项目类别:
-
资助金额:$8.39万
-
财政年份:2012
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Therapeutics of XIAP Degradation by Zinc Chelators
-
批准号:8064259
-
项目类别:
-
资助金额:$31.61万
-
财政年份:2009
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Therapeutics of XIAP Degradation by Zinc Chelators
-
批准号:8259183
-
项目类别:
-
资助金额:$32.31万
-
财政年份:2009
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Therapeutics of XIAP Degradation by Zinc Chelators
-
批准号:8462923
-
项目类别:
-
资助金额:$30.39万
-
财政年份:2009
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Therapeutics of XIAP Degradation by Zinc Chelators
-
批准号:7728815
-
项目类别:
-
资助金额:$32.59万
-
财政年份:2009
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Role of Zinc in Prostate Carcinogenesis
-
批准号:7410058
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2005
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Role of Zinc in Prostate Carcinogenesis
-
批准号:7078585
-
项目类别:
-
资助金额:$29.33万
-
财政年份:2005
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Role of Zinc in Prostate Carcinogenesis
-
批准号:7230435
-
项目类别:
-
资助金额:$28.48万
-
财政年份:2005
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
Role of Zinc in Prostate Carcinogenesis
-
批准号:6966443
-
项目类别:
-
资助金额:$30.05万
-
财政年份:2005
-
负责人:VLADIMIR M KOLENKO
-
依托单位:
海外基金